한국어
English
日本語
中文(简体)
Tabmeco 225mg (Tepotinib Hydrochloride Hydrate)
250mg
Tablet · Prescription medication
Merck Co., Ltd.
Tepotinib hydrochloride hydrate is an anticancer agent used in the treatment of non-small cell lung cancer.
MFDS ingredient code M281717
Tepotinib hydrochloride hydrate belongs to the class of anticancer agents known as MET receptor tyrosine kinase inhibitors. It is primarily used for the treatment of patients with non-small cell lung cancer who have MET gene mutations.
This component blocks the activity of MET receptors on the surface of cancer cells, thereby inhibiting the growth and division of cancer cells. It effectively slows the progression of cancer and reduces tumor size.
Approved uses differ by product. Check each product's information for its actual use.
Tepotinib hydrochloride hydrate is distinguished from other tyrosine kinase inhibitors by its selective inhibition of MET receptors. It is particularly noted for its effectiveness in lung cancer patients with MET gene mutations.
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Even with the same ingredient, dosage and approved uses can differ by strength, dosage form and combined ingredients. Check each product's information before taking it.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
Product approval information is based on drug information provided by the Ministry of Food and Drug Safety.
Ingredient and class descriptions are not part of MFDS data and were written separately by Cashdoc.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.